Salarius Pharmaceuticals (SLRX) Institutional Ownership → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free SLRX Stock Alerts $0.50 +0.02 (+4.04%) (As of 02:01 PM ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Salarius Pharmaceuticals (NASDAQ:SLRX)CurrentInstitutional OwnershipPercentage11.88%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$75.90KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$89.05K Get SLRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Salarius Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SLRX Institutional Buying and Selling by Quarter Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! Salarius Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/13/2024Armistice Capital LLC88,000$57K0.0%-60.9%2.234% 11/15/2023Armistice Capital LLC225,000$148K0.0%+105.2%5.711% 2/13/2023Renaissance Technologies LLC16,342$25K0.0%-97.4%0.717% 2/13/2023Geode Capital Management LLC16,523$25K0.0%-96.0%0.725% 11/15/2022Two Sigma Advisers LP310,000$60K0.0%-5.0%13.608% 11/15/2022Vanguard Group Inc.1,353,373$264K0.0%-14.6%59.411% Get the Latest News and Ratings for SLRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/14/2022Renaissance Technologies LLC634,261$124K0.0%+17.9%28.252% 8/15/2022Millennium Management LLC291,900$61K0.0%+1,350.2%0.520% 8/13/2022Renaissance Technologies LLC538,061$113K0.0%+757.5%0.959% 5/13/2022Renaissance Technologies LLC62,746$25K0.0%-64.9%0.112% 11/15/2021HighTower Advisors LLC26,000$26K0.0%N/A0.058% 11/9/2021BlackRock Inc.116,309$119K0.0%-13.7%0.260% 8/25/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% 8/17/2021X Square Capital LLC100,458$106K0.1%-39.4%0.224% 8/16/2021Maven Securities LTD1,316,205$1.37M0.1%-31.7%2.939% 8/16/2021State Street Corp142,552$151K0.0%N/A0.318% 8/16/2021Sabby Management LLC249,033$264K0.0%-6.7%0.556% 8/16/2021Marshall Wace LLP174,474$185K0.0%+29.6%0.390% 8/13/2021Northern Trust Corp65,022$69K0.0%+25.9%0.145% 8/13/2021Geode Capital Management LLC277,035$293K0.0%+124.4%0.619% 8/13/2021Vanguard Group Inc.1,544,724$1.64M0.0%+8.7%3.450% 8/12/2021Dimensional Fund Advisors LP36,634$39K0.0%-40.8%0.082% 5/19/2021Worth Venture Partners LLC424,800$629K0.3%+17.8%0.949% 5/18/2021Millennium Management LLC28,675$42K0.0%+40.5%0.064% 5/18/2021Silverarc Capital Management LLC1,992,181$2.95M1.6%N/A4.450% 5/14/2021Dimensional Fund Advisors LP61,839$92K0.0%N/A0.138% 5/13/2021Renaissance Technologies LLC237,601$352K0.0%N/A0.531% 5/13/2021Kepos Capital LP548,054$811K0.1%+338.4%1.225% 5/13/2021X Square Capital LLC165,708$245K0.1%+186.4%0.370% 5/12/2021Northern Trust Corp51,648$76K0.0%+248.6%0.115% 5/12/2021Geode Capital Management LLC123,461$182K0.0%+573.5%0.276% 5/12/2021Granite Point Capital Management L.P.1,563,561$2.31M0.1%N/A3.495% 5/6/2021Meitav Dash Investments Ltd.52,000$77K0.0%N/A0.116% 5/6/2021Altium Capital Management LP1,250,110$1.85M0.5%N/A2.795% 3/26/2021Susquehanna International Group LLP33,320$30K0.0%N/A0.074% 2/17/2021Worth Venture Partners LLC360,556$328K0.3%+39.6%1.514% 2/16/2021Squarepoint Ops LLC101,682$93K0.0%+765.5%0.427% 8/14/2020Worth Venture Partners LLC258,249$341K0.2%-15.1%1.892% 5/6/2020Bank of New York Mellon Corp45,187$31K0.0%N/A1.002% 2/20/2020Geode Capital Management LLC18,330$69K0.0%N/A0.406% The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!(Data available from 1/1/2016 forward) SLRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SLRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Salarius Pharmaceuticals shares: Vanguard Group Inc. ($264K), Millennium Management LLC ($61K), Two Sigma Advisers LP ($60K), Armistice Capital LLC ($57K), and Renaissance Technologies LLC ($25K), Geode Capital Management LLC ($25K).Learn more on SLRX's institutional investors. What percentage of Salarius Pharmaceuticals stock is owned by institutional investors? 11.88% of Salarius Pharmaceuticals stock is owned by institutional investors. Learn more on SLRX's institutional investor holdings. Which institutional investors have been buying Salarius Pharmaceuticals stock? The following institutional investors have purchased Salarius Pharmaceuticals stock in the last 24 months: Renaissance Technologies LLC ($571.52K), Millennium Management LLC ($271.77K), and Armistice Capital LLC ($115.36K). How much institutional buying is happening at Salarius Pharmaceuticals? Institutional investors have bought a total of 958,651 shares in the last 24 months. This purchase volume represents approximately $4.47M in transactions. Which Salarius Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Salarius Pharmaceuticals stock in the last 24 months: Renaissance Technologies LLC ($733.77K), Geode Capital Management LLC ($396.61K), Vanguard Group Inc. ($231.65K), Armistice Capital LLC ($137K), and Two Sigma Advisers LP ($16.20K). How much institutional selling is happening at Salarius Pharmaceuticals? Institutional investors have sold a total of 1,515,232 shares in the last 24 months. This volume of shares sold represents approximately $4.00M in transactions. Related Companies: NTBL Institutional Ownership CYCC Institutional Ownership CNSP Institutional Ownership CMND Institutional Ownership BPTH Institutional Ownership CWBR Institutional Ownership LSDI Institutional Ownership QLGN Institutional Ownership INM Institutional Ownership DRMA Institutional Ownership This page (NASDAQ:SLRX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits1970’s computer coder issues shocking A.I. warningTradeSmithSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.